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Growth hormone (GH) is approved in children to treat growth failure in 
several indications including GH deficiency, Turner syndrome and short 
children born small for gestational age,1 and is approved in the USA 
but not in Europe for the treatment of idiopathic short stature (ISS).2 
ISS describes short children with normal GH secretion, with height 
>2 standard deviations (SD) below the corresponding mean height for 
a given age, sex, and population, in whom no identifiable disorder is 
present.3,4 ISS may be familial, in which the child is short compared with 
the reference population but remains within the range of target height 
based on parental height, or non-familial, in which the child is short both 
in comparison with the reference population and the target height based 
on parental height.5 GH therapy in children with ISS may be effective in 
reducing the deficit in height in childhood and improving adult height.3 
Data on the safety of GH therapy in patients from the USA with ISS suggest 
that the safety profile of GH is similar to that reported in other GH-treated 
indications and is not associated with any new safety concerns.6
The aim of this trial was to evaluate the efficacy and safety of recombinant 
human GH (Norditropin® NordiLet®; Novo Nordisk, Bagsværd, Denmark) 
therapy in paediatric patients with ISS in Korea. This prospective trial 
was conducted for registration purposes to seek approval of GH for the 
treatment of ISS in paediatric patients in Korea.
Materials and methods
Trial design
The trial design is shown in Supplementary Figure 1. This trial was 
conducted in accordance with the Declaration of Helsinki7 and 
International Conference of Harmonisation Good Clinical Practice 
Guideline.8 Written informed consent was obtained from patients’ 
parents or legally acceptable representatives before any trial-related 
activities. The trial was conducted at 10 sites in Korea. For each 
investigational site, the adequacy of the research facility to execute the 
Efficacy and Safety Evaluation of Human Growth 
Hormone Therapy in Patients with Idiopathic Short 
Stature in Korea – A Randomised Controlled Trial
Min Ho Jung,1 Byung-Kyu Suh,2 Cheol Woo Ko,3 Kee-Hyoung Lee,4 Dong-Kyu Jin,5 Han-Wook Yoo,6 Jin Soon Hwang,7 Woo Yeong Chung,8 
Heon-Seok Han,9 Vinay Prusty10 and Ho-Seong Kim11
1. The Catholic University of Korea, Yeouido St. Mary’s Hospital, Seoul, South Korea; 2. The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South 
Korea; 3. Kyungpook National University Hospital, Daegu, South Korea; 4. Korea University Anam Hospital, Seoul, South Korea; 5. Samsung Medical Center, 
Sung Kyun Kwan University, Seoul, South Korea; 6. Asan Medical Center, Seoul, South Korea; 7. Ajou University Hospital, Suwon, South Korea; 8. Inje University 
Busan Paik Hospital, Busan, South Korea; 9. Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, South Korea; 
10. Novo Nordisk Pharma Gulf FZ-LLC, Dubai, United Arab Emirates; 11. Severance Hospital, Yonsei University Health System, Seoul, South Korea
Background: This trial evaluated the efficacy and safety of growth hormone (GH) therapy (Norditropin
®; Novo Nordisk, Bagsværd, 
Denmark) in paediatric patients with idiopathic short stature (ISS) in Korea. Methods: This was an open-label, parallel-group, multicentre, 
interventional trial (ClinicalTrials.gov identifier: NCT01778023). Pre-pubertal patients (mean age 6.2 years; height, 107.1 cm) were 
randomised 2:1 to 12 months’ GH treatment (0.469 mg/kg/week; group A, n=36) or 6 months untreated followed by 6 months’ GH treatment 
(group B, n=18). Safety analysis was based on adverse events (AEs) in all GH-treated patients. Results: After 6 months, height velocity (Ht-V), 
change in both height standard deviation score (Ht-SDS) and insulin-like growth factor 1 (mean difference [95% confidence interval {CI}]: 
5.15 cm/year [4.09, 6.21]; 0.57 [0.43, 0.71]; 164.56 ng/mL [112.04, 217.08], respectively; all p<0.0001) were greater in group A than in group B. 
Mean difference in Ht-V for 0–6 months versus 6–12 months was 2.80 cm/year (95% CI 1.55, 4.04) for group A and -4.60 cm/year (95% CI -6.12, 
-3.09; both p<0.0001) for group B. No unexpected AEs were reported. Conclusions: During the first 6 months, height was significantly increased 
in GH-treated patients versus untreated patients with ISS. Safety of GH was consistent with the known safety profile. 
Keywords
Human growth hormone, short stature, idiopathic, clinical trial
Disclosures: Heon-Seok Han received clinical research funding from Novo Nordisk. 
Vinay Prusty was an employee of Novo Nordisk Pharma Korea Ltd at the time of 
the study. Min Ho Jung, Byung-Kyu Suh, Cheol Woo Ko, Kee-Hyoung Lee, Dong-Kyu 
Jin, Han-Wook Yoo, Jin Soon Hwang, Woo Yeong Chung and Ho-Seong Kim have no 
financial or non-financial relationships or activities to declare in relation to this article.
Acknowledgements: The authors thank Mogens Gisselbaek, Lars Nordholm 
and Natasa Savic (Novo Nordisk) for their review and input to the manuscript. 
Medical writing and submission support were provided by Penny Butcher and 
Daria Renshaw of Watermeadow Medical, funded by Novo Nordisk Health Care 
AG. Data from this study were presented as a poster at the Endocrine Society 
(ENDO) 98th Annual Meeting and Expo, 1–4 April 2016, Boston, MA, USA.
Authors’ Contributions: All of the authors were study investigators at the study 
sites so were equally involved in the running of the trial, acquisition of data and 
reviewing the manuscript during development. All authors read and approved the 
final manuscript for submission. The datasets used and/or analysed during the 
current study are available from the corresponding author on reasonable request.
Review Process: Double-blind peer review.
Compliance with Ethics: All procedures were followed in accordance with the  
responsible committee on human experimentation and with the Helsinki Declaration 
of 1975 and subsequent revisions. Informed consent was received from the patients 
involved in this study.
Authorship: All named authors meet the criteria of the International Committee  
of Medical Journal Editors for authorship for this manuscript, take responsibility for the  
integrity of the work as a whole and have given final approval for the version to be published.
Access: This article is freely accessible at touchENDOCRINOLOGY.com  
© Touch Medical Media 2020.
Received: 21 March 2019  Accepted: 7 July 2019  Published Online: 15 October 2019
Citation: European Endocrinology. 2020;16(1):54–9
Corresponding Author: Ho-Seong Kim, Severance Hospital, Yonsei University Health 
System, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea. E: kimho@yuhs.ac
Support: This trial was sponsored by Novo Nordisk Pharma Korea, Ltd. Novo 
Nordisk was responsible for preparing the protocol, providing clinical trial supplies, 
monitoring the trial, supervising activities of the clinical services vendor of 
electronic data capture system, central lab, statistical analysis, data management 
and medical writing, ensuring smooth running of the trial and appropriate safety 
surveillance. No funding was received in the publication of this article.
Efficacy and Safety of Growth Hormone Therapy in Idiopathic Short Stature in Korea
55EUROPEAN ENDOCRINOLOGY
protocol requirements was confirmed by a monitor and the Institutional 
Review Boards of each site before site initiation and any trial activities. 
The protocol (ClinicalTrials.gov identifier: NCT01778023; retrospectively 
registered 24 January 2013), the protocol amendments, the consent 
form, and the subject information sheet were reviewed and approved 
according to local regulations by the Ministry of Food and Drug Safety, 
and by an independent ethics committee and/or Institutional Review 
Board. This trial is the first of its kind for Norditropin worldwide, with the 
purpose of attaining a label extension for its use in the indication of ISS.
This was a 12-month, open-label, randomised, parallel-group, multicentre, 
interventional trial. Patients were randomised 2:1 to a 12-month 
GH-treatment period (group A) or a 6-month no-treatment period followed 
by a 6-month GH treatment period (group B). The randomisation was 
performed by an external contract research organisation. The GH dosage 
used in this trial was 0.469 mg/kg/week, 7 days per week, administered 
subcutaneously in the evening (equivalent to a daily dose of 67 µg/kg/day). 
The GH dose selected in this trial was chosen based on the approved GH 
dose range for short patients born small for gestational age9 due to the 
similarities in growth characteristics between patients with ISS and short 
patients born small for gestational age.10 The sample size was determined 
based on a 2:1 randomisation scheme with a significance level of 5% and 
power of 80%, and 24 completers for group A and 12 completers for group 
B; on the assumption that 30% of patients would withdraw from the trial, 
36 patients were randomised to group A and 18 to group B.
There were six scheduled visits to the clinic (Supplementary Figure 1). 
At the first visit, patients were screened for eligibility. At visit 2, occurring 
between 1 and 21 days after visit 1, GH treatment for group A was 
initiated. Patients attended three interim visits at approximately 3, 6 and 
9 months (each ± 7 days) after visit 2. At visit 4 (6 months after visit 2), 
GH treatment was initiated for group B. Visit 6, at the end of the trial, was 
attended approximately 12 months (± 7 days) after visit 2.
Patients
To be eligible for participation in this trial, patients were required to meet 
all inclusion criteria and none of the exclusion criteria (Supplementary 
Table 1). Key inclusion criteria included pre-pubertal status (males aged 
≥4 to ≤11 years and females aged ≥4 to ≤9 years): an absence of breast 
development in females (Tanner 1 only) and testicular volume <4 mL in 
males, normal thyroid function, peak GH level above 10 ng/mL following 
a GH stimulation test, bone age ≤12 years, and epiphyses confirmed as 
open in patients ≥10 years of age. For the purpose of this trial, children 
with height below the third percentile (based on 2007 Korean national 
growth charts11) and no identifiable disorder were considered as having 
ISS. Key exclusion criteria included a known pituitary hormone deficiency 
(adrenocorticotropic hormone, antidiuretic hormone, follicle-stimulating 
hormone, luteinising hormone, thyroid-stimulating hormone) and 
treatment with any GH in the 12 months before screening; and specific 
types of growth failure including, but not limited to, known chromosomal 
abnormalities associated with growth failure and altered sensitivity to 
GH, e.g., Turner syndrome, Noonan syndrome, Prader–Willi syndrome, 
chromosomal trisomies, chronic renal failure, type 1 diabetes mellitus, 
osteo- and chondrodystrophies, hypochondroplasia, achondroplasia, 
small for gestational age, chronic inflammatory states (such as 
inflammatory bowel disease, rheumatoid arthritis, systemic lupus, cystic 
fibrosis), mitochondrial myopathies, intrauterine growth retardation 
(defined as a birth height and weight both below the fifth percentile and 
not exhibiting catch-up growth by the age of 3 years), and syndromes 
known to be associated with growth failure.
Efficacy assessments
Height (cm) was measured in triplicate by a single observer using 
an identical instrument at visits 1, 2, 3, 4, 5, and 6; corresponding to 
screening, day 0 and months 3, 6, 9, and 12. Height data collected at visits 
2 and 4 were used to calculate the primary endpoint of height velocity 
(Ht-V [cm/year]) after 6 months of treatment. Height data from visits 2–4 
versus data from visits 4–6 were used for the secondary objective of 
comparing Ht-V for the first 6-month treatment period to that of the following 
6-month treatment period in group A, and the exploratory objective of 
comparing Ht-V for the no treatment first 6-month period to that of the 
following 6-month treatment period in group B. In addition, height data were 
used to calculate the confirmatory secondary endpoint of height SD score 
(Ht-SDS). Ht-SDS values were calculated using the growth data from the 
Korea Centers for Disease Control and Prevention.12 Body weight (kg) was 
assessed at trial entry. Parental heights were measured at visit 1 or 2. If it was 
not possible to obtain a parental height measurement, a reported height 
was substituted for a measured height. Insulin-like growth factor 1 (IGF-1) 
and insulin-like growth factor-binding protein 3 (IGFBP-3) were measured 
at visits 1, 3, 4, 5 and 6, and used to calculate the supportive secondary 
endpoint of change in IGF-1 and IGFBP-3 from baseline to 6 months.
Safety assessments
All treatment-emergent adverse events (AEs) reported by the patients 
or observed by the investigator were recorded by the investigator and 
evaluated further. AEs were recorded in all patients who received at least 
one dose of GH and were defined as any untoward event occurring in a 
patient independent of a causal relationship with the trial product. AEs 
were designated as mild (no or transient symptoms that do not interfere 
with daily activities), moderate (marked symptoms with moderate 
interference of daily activities), or severe (considerable [unacceptable] 
interference with daily activities). At each visit, a physical examination 
was performed of the head, ears, eyes, nose, throat, neck, respiratory 
system, cardiovascular system, gastrointestinal system (including mouth), 
genitourinary system, musculoskeletal system, central and peripheral 
nervous systems, and skin, and the findings recorded in the case report 
form. Abnormal findings were reported as clinically significant or not 
clinically significant; worsening of any clinically significant finding from 
the previous visit was reported as an AE. Vital signs, including diastolic 
and systolic blood pressure, pulse, respiratory rate and body temperature 
Table 1: Baseline characteristics
Group A (n=36) Group B (n=15) Total (n=51)
Male, n (%) 19 (52.8) 9 (60.0) 28 (54.9)
Female, n (%) 17 (47.2) 6 (40.0) 23 (45.1)
Mean age, years (SD) 6.3 (1.5) 5.9 (1.2) 6.2 (1.5)
Mean height, cm (SD) 107.7 (8.7)* 105.8 (7.5)† 107.1 (8.3)‡
Mean Ht-SDS (SD) -2.4 (0.4)* -2.2 (0.3)† -2.3 (0.3)‡
Mean weight, kg (SD) 17.8 (3.1)* 16.3 (2.8)† 17.4 (3.0)‡
Male – mean testicular 
volume§, mL (SD) [n]
2.1 (1.3) [19] 1.7 (1.0) [9] 2.0 (1.2) [28]
Female – breast 
development stage§ 1, 
n (%)
17 (100) 6 (100) 23 (100)
Mean IGF-1, ng/mL (SD) 135.9 (64.1) 111.0 (33.3) 128.6 (57.6)
Mean IGFBP-3, µg/mL (SD) 3.5 (0.9) 3.2 (0.5) 3.4 (0.8)
Based on the full analysis set. *n=32, †n=15, ‡n=47.
§ Pubertal stage (Tanner) 
Ht-SDS = height standard deviation score; IGF-1 = insulin-like growth factor 1; 
IGFBP-3 = insulin-like growth factor-binding protein 3; SD = standard deviation.
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were measured throughout the trial. At visits 1 and 3–6, clinical laboratory 
tests were determined for haematology, urinalysis, biochemistry, lipids, 
and metabolic and thyroid functions. Bone age was assessed via plain 
X-rays of the left hand and wrist obtained at visits 1, 4 and 6.
Statistical analysis
As defined in the trial protocol, the primary endpoint of Ht-V after 6 months of 
treatment was converted per 365 days for completers and last observation 
carried forward applied for withdrawals; the endpoint was analysed using an 
analysis of variance (ANOVA) model with group and sex as fixed effects, and 
age as a covariate. The confirmatory secondary endpoint and supportive 
secondary endpoints of change in IGF-1 and IGFBP-3 from baseline to 
6 months were analysed using an ANOVA model with group and sex as fixed 
effects, and age and baseline Ht-SDS as covariates. P values and confidence 
intervals (CIs) are presented together with the estimated mean effect (least 
square [LS] means) for each group and estimated mean group difference. 
The supportive secondary endpoint of Ht-V during the first 6 months and last 
6 months for group A were compared using a paired t-test. An exploratory 
endpoint comparing Ht-V during the first and last 6 months for group B was 
evaluated using a paired t-test, and a 95% CI of the mean was calculated 
based on t-distribution.
A post hoc analysis was conducted on the primary efficacy endpoint and 
secondary confirmatory efficacy endpoint. This was done by repeating 
the analyses for all patients, but with data for patients who had height 
data missing at baseline replaced with their height data at screening to 
determine if the missing baseline height data affected the efficacy results.
Results
Patient characteristics
A total of 70 patients were screened, of whom, 16 were ineligible for 
inclusion as a result of failing to meet at least one of the specified 
inclusion criteria or for meeting at least one of the exclusion criteria 
(Supplementary Table 2). The remaining 54 patients were randomised 
2:1 to group A (n=36) or group B (n=18). Three of the patients 
randomised to group B withdrew informed consent before being 
exposed to treatment. Baseline characteristics were similar between 
the two treatment groups (Table 1). At the start of the trial, the overall 
mean age was 6.2 years (SD 1.5), mean height was 107.1 cm (SD 8.3), 
and mean weight was 17.4 kg (SD 3.0).
Height velocity
Ht-V by treatment visit is displayed in Figure 1. For the primary endpoint 
of Ht-V after 6 months of treatment, group A (12.02 cm/year) was higher 
than group B (no treatment; 6.87 cm/year), with an LS means difference 
of 5.15 cm/year (95% CI 4.09, 6.21; p<0.0001) (Table 2). The results of the 
post hoc analysis were similar to those of the primary analysis, with a 
mean difference between group A and group B of 5.19 cm/year (95% CI 
4.09, 6.19; p<0.0001).
The mean Ht-V for group A was 12.0 cm/year (SD 1.8) and 10.6 cm/year 
(SD 1.5) at months 6 and 12, respectively; a comparison of Ht-V for the first 
and last 6 months demonstrated a statistically significant duration contrast 
with an LS means difference of 2.80 cm/year (95% CI 1.55, 4.04; p<0.0001). 
For group B, the mean Ht-V was 6.9 cm/year (SD 1.3) and 9.2 cm/year (SD 
0.8) at months 6 (no treatment) and 12 (after 6 months’ GH treatment), 
respectively; the duration contrast between the first and last 6 months was 
statistically significant with an LS means difference of -4.60 cm/year (95% CI 
-6.12, -3.09; p<0.0001) (Table 2).
Height SDS
Ht-SDS by treatment visit is displayed in Figure 2, calculated from height 
data from visits 2, 4 and 6. Change in Ht-SDS (secondary endpoint) 
after 6 months’ GH treatment was higher for group A (0.76) than for the 
no-treatment group B (0.19), with an LS means difference of 0.57 (95% CI 
0.43, 0.71; p<0.0001) (Table 2). A similar result was seen in the post hoc 
analysis, with an LS means difference of 0.57 (95% CI 0.44, 0.70; p<0.0001).
Insulin-like growth factor 1 and insulin-like growth 
factor-binding protein 3
IGF-1 concentration by treatment visit is shown in Figure 3. After 
6 months of treatment, the change in IGF-1 concentration for group A 
Table 2: Summary of efficacy endpoints
Group A (n=36) Group B (n=15) Estimated treatment difference* (95% CI) P value
Primary endpoint
Ht-V (cm/year) 12.02 6.87 5.15 (4.09, 6.21) <0.0001
Confirmatory secondary endpoint
Ht-SDS change from baseline at 6 months 0.76 0.19 – –
Ht-SDS at 6 months -1.56 -2.13 0.57 (0.43, 0.71) <0.0001
Supportive secondary endpoint
IGF-1, ng/mL At 6 months 321.18 156.61 – –
Change from baseline 192.58 28.03 164.56 (112.04, 217.08) <0.0001
IGFBP-3, µg/mL At 6 months 4.29 3.62 – –
Change from baseline 0.89 0.22 0.67 (-0.04, 1.38) 0.06
Ht-V endpoint
Ht-V at 6 months 
cm/year (SD)
Ht-V at 12 months 
cm/year (SD)
Estimated treatment difference 
(Ht-V at 0–6 months minus Ht-V at 
6–12 months) cm/year (95% CI)
P value
Group A 12.0 (1.8) 10.6 (1.5) 2.80 (1.55, 4.04) <0.0001
Group B 6.9 (1.3)† 9.2 (0.8)† -4.60 (-6.12, -3.09) <0.0001
*Least square means. Based on the full analysis set.
†Patients in group B were not treated during the first 6 months of the study and received growth hormone during the second 6 months of the study.
CI = confidence interval; Ht-SDS = height standard deviation score; Ht-V = height velocity; IGF-1 = insulin-like growth factor 1; IGFBP-3 = insulin-like growth factor-binding protein 3; 
SD = standard deviation.
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was 192.58 ng/mL, and at the end of the 6-month no-treatment period for 
group B, the change in IGF-1 concentration was 28.03 ng/mL, resulting in 
an estimated treatment difference of 164.56 ng/mL (95% CI 112.04, 217.08; 
p<0.0001) (Table 2). Change in IGFBP-3 after 6 months of treatment was 
0.89 µg/mL for group A and 0.22 µg/mL for group B, with an estimated 
treatment difference of 0.67 µg/mL (95% CI -0.04, 1.38; p=0.06) (Table 2).
Safety evaluation
Overall, 95 AEs were reported in 36 patients during the trial (from start 
of GH treatment to last visit). After 12 months, a similar proportion 
of patients reported AEs in group A (69.4%) and group B (73.3%). Four 
serious AEs were reported in four patients (11.1%) in group A, and two 
in two patients (13.3%) in group B. In group A, there was one event each 
of hydrocoele, pharyngotonsillitis, tonsillar hypertrophy and Kawasaki’s 
disease. In group B, there was one event of pneumonia and one event of 
tonsillar hypertrophy. There were no AEs leading to withdrawal in this trial. 
All AEs were either mild or moderate in severity (affecting 61.1% 
and 16.7%, respectively, of patients in group A and 53.3% and 26.7%, 
respectively, in group B) (Table 3). No deaths were reported. The most 
frequently reported AEs, occurring in at least 5% of patients in both groups, 
were nasopharyngitis and upper respiratory tract infections (Table 3). A 
total of three AEs were deemed possibly related to trial product (fatigue, 
contusion and dizziness), occurring in two patients in group A.
Discussion
The results of this trial show that 6 months of GH treatment 
(0.469 mg/kg/week) significantly increased height in patients with ISS in 
Korea, as evaluated by Ht-V and Ht-SDS, compared with no treatment. 
In a report of 751 patients with ISS enrolled in an observational study, 
Ross et al.13 reported an improvement in Ht-SDS of 0.60 and 0.71 for male 
and female patients, respectively, following 1 year of GH therapy with an 
average weekly dose of 0.350 mg/kg. Patients in that study were slightly 
older than those in the present trial (mean age at baseline was 11.2 years 
[SD 3.06] versus 6.2 years [SD 1.5] in the present trial) but had a similar 
height deficit at treatment start (mean Ht-SDS was -2.3 [SD 0.75]).13 The 
lower GH dose of 0.350 mg/kg/week, in comparison to 0.469 mg/kg/week 
in the present trial, as well as the slightly older age at treatment start, 
may contribute to the difference in Ht-SDS improvements. This was 
reported in another study, by Albertsson-Wikland et al.,14 which showed 
a dose-dependent improvement in Ht-SDS, with patients receiving 
0.469 mg/kg/week GH having a greater improvement in mean (SD) Ht-
SDS than patients who received 0.231 mg/kg/ week (0.76 [SD 0.22] versus 
0.53 [SD 0.20], respectively). In addition to GH dose, response to GH 
therapy has been shown to be influenced by a variety of factors, including 
adherence, gender, age at treatment start, and pubertal status.13,15,16
In the present trial, it was noteworthy that the gradient in Ht-SDS 
(Figure 2) diverged between groups for the first 6 months, but then 
increased in group B after month 6 when GH was initiated. From this 
point, the gradient for group B appeared to run approximately in parallel 
with that for group A. Consequently, at the end of the trial, although the 
Ht-SDS for group B lagged behind that of group A, demonstrating that 
the 6-month delay in initiating GH treatment in group B had resulted in a 
reduced overall growth response at 1 year, it is possible that continued 
treatment in group B may have allowed those patients to achieve a 
Figure 3: Insulin-like growth factor 1 by treatment visit
Based on the full analysis set. Data are observed mean (standard deviation).  
*Change from baseline 192.58 ng/mL for group A and 28.03 ng/mL for group B, 
estimated treatment contrast 164.56 ng/mL, p<0.0001.  
GH = growth hormone; IGF-1 = insulin-like growth factor 1.
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Figure 2: Height standard deviation score by treatment visit
Based on the full analysis set. Data are observed mean (standard deviation).  
*Change from baseline 0.76 for group A and 0.19 for group B, estimated treatment 
contrast 0.57, p<0.0001.  
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Figure 1: Height velocity by treatment visit
Based on the full analysis set. Data are observed mean (standard deviation). 
*Estimated treatment contrast 5.15 cm/year, p<0.0001.  
GH = growth hormone; Ht-V = height velocity.
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similar height outcome to those in group A. However, accumulated 
data support the potential importance of initiating treatment as early as 
possible to achieve optimal height outcomes, although this hypothesis 
requires further investigation over longer time periods. Furthermore, ISS 
constitutes a diverse population in which there can be varied responses 
to GH treatment.
Improvements in Ht-V and Ht-SDS during GH therapy were accompanied 
by an increase from baseline in IGF-1 and IGFBP-3, although the 
difference between treatment groups A and B was only significant for 
IGF-1. The post hoc analyses carried out on Ht-V and Ht-SDS data showed 
that replacement with screening data for the four patients with missing 
baseline height data did not affect the efficacy results.
In line with other reports of GH therapy in pre-pubertal patients with 
ISS,14,17 there were no unexpected AEs observed during this trial and GH 
treatment was generally well tolerated. Overall, the safety profiles were 
similar between treatment groups, with no patterns or clustering of AEs 
or serious AEs.
A limitation of this trial is that analyses were not performed to 
correct for parental height. This would account for genetic factors that 
may result in short stature, although such adjustments may only be 
appropriate in patients with parents of normal stature.18 Furthermore, 
the open-label design of this trial might have led to significant bias in 
measurement that could result in an overestimation of the effects of GH 
therapy on growth.
Conclusions
In conclusion, the results of this trial show that 6 months of GH treatment 
(0.469 mg/kg/week) significantly increased height in patients with ISS in 
Korea compared with 6 months of no treatment, as evaluated by Ht-V. 
Furthermore, GH treatment significantly increased Ht-SDS and was 
associated with increased IGF-1 levels compared with no treatment. 
No unexpected safety issues were reported and GH treatment was 
well tolerated.
Supplementary material
Supplementary Figure 1: Trial design. Graphical representation of  
trial design.
Supplementary  Table 1: Inclusion and exclusion criteria. 
Documentation of full inclusion/exclusion criteria.
Supplementary Table 2: Patient disposition. Display of patient flow 
through the trial. 
Table 3: Summary of treatment-emergent adverse events
Group A (n=36) Group B (n=15) Total (n=51)
Number of patients (%) Number of events Number of patients (%) Number of events Number of patients (%) Number of events
Events 25 (69.4) 70 11 (73.3) 25 36 (70.6) 95
Serious
Yes 4 (11.1) 4 2 (13.3) 2 6 (11.8) 6
No 24 (66.7) 66 10 (66.7) 23 34 (66.7) 89
Severity
Mild 22 (61.1) 59 8 (53.3) 18 30 (58.8) 77
Moderate 6 (16.7) 11 4 (26.7) 7 10 (19.6) 18
Adverse events occurring in ≥5% of patients in either group
Events 20 (55.6) 56 11 (73.3) 24 31 (60.8) 81
Eye disorders 0 (0.0) 0 1 (6.7) 1 1 (2.0) 1
General disorders and administration site conditions
Chest pain 0 (0.0) 0 1 (6.7) 1 1 (2.0) 1
Pyrexia 2 (5.6) 2 0 (0.0) 0 2 (3.9) 2
Infections and infestations
Conjunctivitis 0 (0.0) 0 1 (6.7) 1 1 (2.0) 1
Influenza 3 (8.3) 3 0 (0.0) 0 3 (5.9) 3
Nasopharyngitis 15 (41.7) 43 7 (46.7) 14 22 (43.1) 57
Pharyngotonsillitis 2 (5.6) 2 0 (0.0) 0 2 (3.9) 2
Pneumonia 0 (0.0) 0 1 (6.7) 1 1 (2.0) 1
Rhinitis 0 (0.0) 0 2 (13.3) 3 2 (3.9) 3
Upper respiratory 
tract infection
3 (8.3) 3 1 (6.7) 1 4 (7.8) 4
Respiratory, thoracic and mediastinal disorders
Rhinitis allergic 0 (0.0) 0 1 (6.7) 1 1 (2.0) 1
Tonsillar 
hypertrophy
0 (0.0) 0 1 (6.7) 1 1 (2.0) 1
Skin and subcutaneous tissue disorders
Dermatitis 0 (0.0) 0 1 (6.7) 1 1 (2.0) 1
Urticaria 3 (8.3) 3 0 (0.0) 0 3 (5.9) 3
Data based on the safety analysis set.
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